Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival

Andrew B. Adams, Nozomu Shirasugi, Thomas R. Jones, Megan M. Durham, Elizabeth A. Strobert, Shannon Cowan, Phyllis Rees, Rose Hendrix, Karen Price, Norma S Kenyon, David Hagerty, Robert Townsend, Dianne Hollenbaugh, Thomas C. Pearson, Christian P. Larsen

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although CM220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti-CD40 was tested alone and in combination with a rationally designed, high affinity variant of CTLA4-Ig, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.

Original languageEnglish
Pages (from-to)542-550
Number of pages9
JournalJournal of Immunology
Volume174
Issue number1
StatePublished - Jan 1 2005

Fingerprint

Allografts
Monoclonal Antibodies
Islets of Langerhans Transplantation
Cell- and Tissue-Based Therapy
Primates
Antiviral Agents
Immunity
Rodentia
Abatacept
Clinical Trials
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Adams, A. B., Shirasugi, N., Jones, T. R., Durham, M. M., Strobert, E. A., Cowan, S., ... Larsen, C. P. (2005). Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. Journal of Immunology, 174(1), 542-550.

Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. / Adams, Andrew B.; Shirasugi, Nozomu; Jones, Thomas R.; Durham, Megan M.; Strobert, Elizabeth A.; Cowan, Shannon; Rees, Phyllis; Hendrix, Rose; Price, Karen; Kenyon, Norma S; Hagerty, David; Townsend, Robert; Hollenbaugh, Dianne; Pearson, Thomas C.; Larsen, Christian P.

In: Journal of Immunology, Vol. 174, No. 1, 01.01.2005, p. 542-550.

Research output: Contribution to journalArticle

Adams, AB, Shirasugi, N, Jones, TR, Durham, MM, Strobert, EA, Cowan, S, Rees, P, Hendrix, R, Price, K, Kenyon, NS, Hagerty, D, Townsend, R, Hollenbaugh, D, Pearson, TC & Larsen, CP 2005, 'Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival', Journal of Immunology, vol. 174, no. 1, pp. 542-550.
Adams AB, Shirasugi N, Jones TR, Durham MM, Strobert EA, Cowan S et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. Journal of Immunology. 2005 Jan 1;174(1):542-550.
Adams, Andrew B. ; Shirasugi, Nozomu ; Jones, Thomas R. ; Durham, Megan M. ; Strobert, Elizabeth A. ; Cowan, Shannon ; Rees, Phyllis ; Hendrix, Rose ; Price, Karen ; Kenyon, Norma S ; Hagerty, David ; Townsend, Robert ; Hollenbaugh, Dianne ; Pearson, Thomas C. ; Larsen, Christian P. / Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. In: Journal of Immunology. 2005 ; Vol. 174, No. 1. pp. 542-550.
@article{fc7227ce4d3148ada58c581f84b6071a,
title = "Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival",
abstract = "In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although CM220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti-CD40 was tested alone and in combination with a rationally designed, high affinity variant of CTLA4-Ig, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.",
author = "Adams, {Andrew B.} and Nozomu Shirasugi and Jones, {Thomas R.} and Durham, {Megan M.} and Strobert, {Elizabeth A.} and Shannon Cowan and Phyllis Rees and Rose Hendrix and Karen Price and Kenyon, {Norma S} and David Hagerty and Robert Townsend and Dianne Hollenbaugh and Pearson, {Thomas C.} and Larsen, {Christian P.}",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "174",
pages = "542--550",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival

AU - Adams, Andrew B.

AU - Shirasugi, Nozomu

AU - Jones, Thomas R.

AU - Durham, Megan M.

AU - Strobert, Elizabeth A.

AU - Cowan, Shannon

AU - Rees, Phyllis

AU - Hendrix, Rose

AU - Price, Karen

AU - Kenyon, Norma S

AU - Hagerty, David

AU - Townsend, Robert

AU - Hollenbaugh, Dianne

AU - Pearson, Thomas C.

AU - Larsen, Christian P.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although CM220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti-CD40 was tested alone and in combination with a rationally designed, high affinity variant of CTLA4-Ig, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.

AB - In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although CM220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti-CD40 was tested alone and in combination with a rationally designed, high affinity variant of CTLA4-Ig, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.

UR - http://www.scopus.com/inward/record.url?scp=19944412462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944412462&partnerID=8YFLogxK

M3 - Article

C2 - 15611281

AN - SCOPUS:19944412462

VL - 174

SP - 542

EP - 550

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -